Claims for Patent: 7,238,357

Summary for Patent: 7,238,357

Title:	Methods for treating ulcers and gastroesophageal reflux disease
Abstract:	Methods for treating peptic ulcers and methods for treating gastroesophageal reflux disease by oral administration of a botulinum toxin.
Inventor(s):	Barron; Richard L. (Trabuco Canyon, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	10/288,734
Patent Claims:	1. A method for treating gastroesophageal reflux disease, the method comprising the step of oral ingestion of a therapeutically effective amount of a botulinum toxin by a patient with gastroesophageal reflux disease, thereby reducing a symptom of the gastroesophageal reflux disease, wherein the symptom is selected from the group consisting of heartburn, belching, regurgitation of food, nausea, vomiting, hoarseness of voice, sore throat, difficulty swallowing and cough, wherein the amount of the botulinum toxin is from about 50 to about 2000 units. 2. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G. 3. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A. 4. The method of claim 1, wherein the botulinum toxin is botulinum toxin type B. 5. The method of claim 1, wherein the therapeutically effective amount of a botulinum toxin is provided in the form of a tablet or capsule or geltab. 6. The method of claim 1, wherein the symptom is reduced within two weeks of oral ingestion of the therapeutically effective amount of a botulinum toxin. 7. A method for treating a gastroesophageal reflux disease, the method comprising the step of oral ingestion of a therapeutically effective amount of a botulinum toxin by a patient with gastroesophageal reflux disease, thereby reducing a symptom of the gastroesophageal reflux disease, wherein the symptom is selected from the group consisting of heartburn, belching, regurgitation of food, nausea, vomiting, hoarseness of voice, sore throat, difficulty swallowing and cough, wherein the amount of the botulinum toxin is ingested each day for four days. 8. The method of claim 7, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G. 9. A method for treating a symptom of gastroesophageal reflux disease that cannot be treated by an antacid, the method comprising the step of oral ingestion of a therapeutically effective amount of a botulinum toxin by a patient with a gastroesophageal reflux disease, thereby reducing the symptom of the gastroesophageal reflux disease that cannot be treated by the antacid. 10. The method of claim 9, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G. 11. A method for treating a symptom of gastroesophageal reflux disease that cannot be treated by a histamine H2 receptor blocker, the method comprising the step of oral ingestion of a therapeutically effective amount of a botulinum toxin by a patient with gastroesophageal reflux disease, thereby reducing the symptom of the gastroesophageal reflux disease that cannot be treated by the histamine H2 receptor blocker. 12. The method of claim 11, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G.

Details for Patent 7,238,357

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2039-03-29
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2039-03-29